310 related articles for article (PubMed ID: 24242874)
1. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
[TBL] [Abstract][Full Text] [Related]
2. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Liepelt A; Tacke F
Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
[TBL] [Abstract][Full Text] [Related]
3. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
4. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
6. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation.
Hong F; Tuyama A; Lee TF; Loke J; Agarwal R; Cheng X; Garg A; Fiel MI; Schwartz M; Walewski J; Branch A; Schecter AD; Bansal MB
Hepatology; 2009 Jun; 49(6):2055-67. PubMed ID: 19434726
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
8. Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma.
Xu Y; Fang F; Jiao H; Zheng X; Huang L; Yi X; Zhao W
Cancer Immunol Immunother; 2019 Dec; 68(12):1959-1969. PubMed ID: 31641797
[TBL] [Abstract][Full Text] [Related]
9. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Liu CH; Chan KM; Chiang T; Liu JY; Chern GG; Hsu FF; Wu YH; Liu YC; Chen Y
Mol Pharm; 2016 Jul; 13(7):2253-62. PubMed ID: 27224003
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
11. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
12. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
[TBL] [Abstract][Full Text] [Related]
13. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Sung YC; Liu YC; Chao PH; Chang CC; Jin PR; Lin TT; Lin JA; Cheng HT; Wang J; Lai CP; Chen LH; Wu AY; Ho TL; Chiang T; Gao DY; Duda DG; Chen Y
Theranostics; 2018; 8(4):894-905. PubMed ID: 29463989
[TBL] [Abstract][Full Text] [Related]
14. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Lu L; Lu M; Pei Y; Chen J; Qin L; Zhu W; Jia H
Acta Biochim Biophys Sin (Shanghai); 2015 Dec; 47(12):988-96. PubMed ID: 26607439
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
17. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
18. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
19. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L
Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275
[No Abstract] [Full Text] [Related]
20. EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway.
Wang Y; Yu H; Shan Y; Tao C; Wu F; Yu Z; Guo P; Huang J; Li J; Zhu Q; Yu F; Song Q; Shi H; Zhou M; Chen G
J Exp Clin Cancer Res; 2016 Apr; 35():65. PubMed ID: 27066828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]